In this review:
New strategies in early triple-negative breast cancer
How should we treat patients after progression on CDK4/6 inhibitors?
Debate: That NACT has little role for ER+ HER2- breast cancer
Debate: That PET-CT alone should be the diagnostic tool of choice for metastatic workup for stage 2/3 patients
Debate: After treatment response of de novo metastatic breast cancer, how should the primary lesion be managed?
Breast carcinoma with medullary features
Risk of ipsilateral breast tumour recurrence in breast conserving surgery after neoadjuvant therapy
Examination of the appropriate treatment for elderly breast cancer patients over 80
Vision for breast cancer 2025
Please login below to download this issue (PDF)